Furthermore, GL-V9 successfully prevented colitis by inhibiting the elevated levels of IL-1β, IL-6 and TNF-α in serum and the high-production of IL-1β, IL-6, TNF-α, MIP-1α and IFN-γ in colons (Figure 3A and 3B). Here, CCL3 is linked to colitis.